Disappointment for Australian company Actinogen Medical (ASX:ACW) with the release of data from its phase 2 clinical trial (XanADu) investigating its investigative therapy Xanamem in patients with mild dementia due to Alzheimer’s disease. …
Latest Video
New Stories
-
Greg Hunt could up the ante with speculated appointment
November 15, 2019 - - Latest News -
Malaria researcher wins GSK Award for Research Excellence
November 15, 2019 - - Latest News -
Australian company doses first patient in 'tumour agnostic' study
November 15, 2019 - - Latest News -
Stakeholders leave meeting none-the-wiser on negotiation progress
November 15, 2019 - - Latest News -
PHARMAC switch now blamed for three deaths
November 14, 2019 - - Latest News -
7CPA deal unlikely in 2019
November 14, 2019 - - Latest News -
New report highlights system challenge for Alzheimer's treatment
November 14, 2019 - - Latest News